Not Yet Enrolling

Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

J1I-MC-GZBY -

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and inadequate glycemic control.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Type 2 Diabetes
What the trial is testing?
retatrutide
Could I receive a Placebo?
Yes
Enrollment Goal
480
Trial Dates
May 1, 2024 - Jul 2026
How long will I be in the trial?
The study will last about 11 months and may include up to 11 visits.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Be 18 years or older

  • Have a BMI of ≥ 23.0 kg/m^2

  • Have T2D

  • Have high blood sugar as measured by hemoglobin A1C (HbA1c 7% to 9.5%)

Participants Must Not:

  • Have T1D

  • Have had or plan to have a surgical treatment for obesity

  • Have history of an inflamed pancreas (pancreatitis)

  • Have used any weight loss drugs within the last 3 months

  • Have an eGFR <15 mL/min/1.73 m^2 at screening

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources